vs
如新（NUS）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
如新的季度营收约是REPLIGEN CORP的1.9倍（$370.3M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 3.9%，领先2.8%），REPLIGEN CORP同比增速更快（13.6% vs -16.9%），REPLIGEN CORP自由现金流更多（$17.6M vs $5.9M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -5.8%）
如新企业集团是一家美国多层次直销企业，主打研发并销售个人护理产品与营养膳食补充产品，旗下拥有Nu Skin及Pharmanex两大品牌，目前已在全球54个市场开展业务，依托约120万独立销售代表的销售网络覆盖全球市场。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
NUS vs RGEN — 直观对比
营收规模更大
NUS
是对方的1.9倍
$197.9M
营收增速更快
RGEN
高出30.5%
-16.9%
净利率更高
RGEN
高出2.8%
3.9%
自由现金流更多
RGEN
多$11.7M
$5.9M
两年增速更快
RGEN
近两年复合增速
-5.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $370.3M | $197.9M |
| 净利润 | $14.5M | $13.3M |
| 毛利率 | 70.7% | 52.5% |
| 营业利润率 | 6.3% | 9.0% |
| 净利率 | 3.9% | 6.7% |
| 营收同比 | -16.9% | 13.6% |
| 净利润同比 | 140.1% | 143.9% |
| 每股收益（稀释后） | $0.27 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NUSRGEN
| Q4 25 | $370.3M | $197.9M | ||
| Q3 25 | $364.2M | $188.8M | ||
| Q2 25 | $386.1M | $182.4M | ||
| Q1 25 | $364.5M | $169.2M | ||
| Q4 24 | $445.6M | $174.1M | ||
| Q3 24 | $430.1M | $154.9M | ||
| Q2 24 | $439.1M | $154.1M | ||
| Q1 24 | $417.3M | $151.3M |
净利润NUSRGEN
| Q4 25 | $14.5M | $13.3M | ||
| Q3 25 | $17.1M | $14.9M | ||
| Q2 25 | $21.1M | $14.9M | ||
| Q1 25 | $107.5M | $5.8M | ||
| Q4 24 | $-36.1M | $-30.3M | ||
| Q3 24 | $8.3M | $-654.0K | ||
| Q2 24 | $-118.3M | $3.3M | ||
| Q1 24 | $-533.0K | $2.1M |
毛利率NUSRGEN
| Q4 25 | 70.7% | 52.5% | ||
| Q3 25 | 70.5% | 53.2% | ||
| Q2 25 | 68.8% | 50.0% | ||
| Q1 25 | 67.8% | 53.6% | ||
| Q4 24 | 62.7% | 26.1% | ||
| Q3 24 | 70.1% | 50.0% | ||
| Q2 24 | 70.0% | 49.8% | ||
| Q1 24 | 70.5% | 49.5% |
营业利润率NUSRGEN
| Q4 25 | 6.3% | 9.0% | ||
| Q3 25 | 5.9% | 8.9% | ||
| Q2 25 | 8.0% | 7.6% | ||
| Q1 25 | -2.7% | 3.9% | ||
| Q4 24 | -11.9% | -17.7% | ||
| Q3 24 | 4.2% | -5.1% | ||
| Q2 24 | -28.6% | 1.0% | ||
| Q1 24 | 2.1% | 1.3% |
净利率NUSRGEN
| Q4 25 | 3.9% | 6.7% | ||
| Q3 25 | 4.7% | 7.9% | ||
| Q2 25 | 5.5% | 8.2% | ||
| Q1 25 | 29.5% | 3.4% | ||
| Q4 24 | -8.1% | -17.4% | ||
| Q3 24 | 1.9% | -0.4% | ||
| Q2 24 | -26.9% | 2.2% | ||
| Q1 24 | -0.1% | 1.4% |
每股收益（稀释后）NUSRGEN
| Q4 25 | $0.27 | $0.24 | ||
| Q3 25 | $0.34 | $0.26 | ||
| Q2 25 | $0.43 | $0.26 | ||
| Q1 25 | $2.14 | $0.10 | ||
| Q4 24 | $-0.73 | $-0.55 | ||
| Q3 24 | $0.17 | $-0.01 | ||
| Q2 24 | $-2.38 | $0.06 | ||
| Q1 24 | $-0.01 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $239.8M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $805.2M | $2.1B |
| 总资产 | $1.4B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资NUSRGEN
| Q4 25 | $239.8M | $767.6M | ||
| Q3 25 | $253.0M | $748.7M | ||
| Q2 25 | $265.4M | $708.9M | ||
| Q1 25 | $213.6M | $697.2M | ||
| Q4 24 | $198.0M | $757.4M | ||
| Q3 24 | $237.8M | $784.0M | ||
| Q2 24 | $232.9M | $809.1M | ||
| Q1 24 | $221.2M | $780.6M |
总债务NUSRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益NUSRGEN
| Q4 25 | $805.2M | $2.1B | ||
| Q3 25 | $799.8M | $2.1B | ||
| Q2 25 | $787.8M | $2.1B | ||
| Q1 25 | $754.0M | $2.0B | ||
| Q4 24 | $651.5M | $2.0B | ||
| Q3 24 | $706.9M | $2.0B | ||
| Q2 24 | $686.2M | $2.0B | ||
| Q1 24 | $810.2M | $2.0B |
总资产NUSRGEN
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.4B | $2.9B | ||
| Q1 25 | $1.4B | $2.9B | ||
| Q4 24 | $1.5B | $2.8B | ||
| Q3 24 | $1.6B | $2.8B | ||
| Q2 24 | $1.6B | $2.9B | ||
| Q1 24 | $1.7B | $2.8B |
负债/权益比NUSRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.6M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $5.9M | $17.6M |
| 自由现金流率自由现金流/营收 | 1.6% | 8.9% |
| 资本支出强度资本支出/营收 | 2.9% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.15× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $46.0M | $93.9M |
8季度趋势，按日历期对齐
经营现金流NUSRGEN
| Q4 25 | $16.6M | $25.7M | ||
| Q3 25 | $27.5M | $48.1M | ||
| Q2 25 | $35.8M | $28.6M | ||
| Q1 25 | $389.0K | $15.0M | ||
| Q4 24 | $25.8M | $39.2M | ||
| Q3 24 | $31.4M | $49.3M | ||
| Q2 24 | $51.2M | $42.2M | ||
| Q1 24 | $3.3M | $44.7M |
自由现金流NUSRGEN
| Q4 25 | $5.9M | $17.6M | ||
| Q3 25 | $17.6M | $43.4M | ||
| Q2 25 | $35.8M | $21.5M | ||
| Q1 25 | $-13.2M | $11.4M | ||
| Q4 24 | $13.2M | $33.6M | ||
| Q3 24 | $22.8M | $42.3M | ||
| Q2 24 | $43.1M | $37.4M | ||
| Q1 24 | $-9.0M | $36.4M |
自由现金流率NUSRGEN
| Q4 25 | 1.6% | 8.9% | ||
| Q3 25 | 4.8% | 23.0% | ||
| Q2 25 | 9.3% | 11.8% | ||
| Q1 25 | -3.6% | 6.8% | ||
| Q4 24 | 3.0% | 19.3% | ||
| Q3 24 | 5.3% | 27.3% | ||
| Q2 24 | 9.8% | 24.3% | ||
| Q1 24 | -2.1% | 24.0% |
资本支出强度NUSRGEN
| Q4 25 | 2.9% | 4.1% | ||
| Q3 25 | 2.7% | 2.5% | ||
| Q2 25 | 0.0% | 3.9% | ||
| Q1 25 | 3.7% | 2.1% | ||
| Q4 24 | 2.8% | 3.2% | ||
| Q3 24 | 2.0% | 4.5% | ||
| Q2 24 | 1.9% | 3.1% | ||
| Q1 24 | 2.9% | 5.5% |
现金转化率NUSRGEN
| Q4 25 | 1.15× | 1.93× | ||
| Q3 25 | 1.61× | 3.23× | ||
| Q2 25 | 1.69× | 1.92× | ||
| Q1 25 | 0.00× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.79× | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NUS
| Other | $161.9M | 44% |
| Mainland China Segment | $52.0M | 14% |
| Southeast Asia Pacific Segment | $50.5M | 14% |
| Europe And Africa Segment | $41.8M | 11% |
| Hong Kong Taiwan Segment | $29.6M | 8% |
| South Korea Segment | $28.4M | 8% |
| Rhyz Other Segment | $6.1M | 2% |
RGEN
暂无分部数据
